Novita to Present Additional Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at American Association for Cancer Research Immuno-Oncology Conference 2025 (AACR IO) Annual Meeting

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Novita Pharmaceuticals, Inc., a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today announced that the Company will present additional data from the Phase 2 trial of its novel fascin inhibitor, NP-G2-044, at the American Association for Cancer Research Immuno-Oncology Conference 2025 (AACR IO), being held February 23-26, 2025 in Los Angeles, California.

Details of the poster presentation are below.

Title: Phase 2 Study of NP-G2-044, a Novel Fascin Inhibitor, in Combination with Anti-PD-1 Therapy in Patients with Solid Tumors Resistant to Prior Anti-PD-1 Therapy
Session: Poster Session B
Date and Time: Tuesday, February 25, 2025 at 1:45-4:00 p.m. PT            
Presenting Author: Anup Kasi, M.D., M.P.H., University of Kansas Medical Center

The poster will be available on Novita's website following the presentation. For more details about the AACR IO Annual Meeting, please visit their website here.

About Novita's Pioneering Research in Fascin Inhibition
Cancer metastasis is the primary cause of over 90% of cancer-related deaths, yet there is currently no drug on the market specifically targeting metastasis. Furthermore, while Immuno-Oncology (IO) therapies, particularly immune checkpoint inhibitors, have made significant strides in cancer treatment, a large proportion of patients do not respond to existing IO treatments. Novita aims to address both of these critical medical needs by developing fascin inhibitors, which target a key protein involved in tumor cell motility and highly expressed in tumor cells and antigen-presenting cells within tumor tissues. The Company's lead asset, NP-G2-044, is a small-molecule fascin inhibitor that has demonstrated the ability to block metastasis in both preclinical and clinical studies. Additionally, when combined with immune checkpoint inhibitors, NP-G2-044 has shown potential to reinvigorate anti-tumor immune responses. Novita's multicenter Phase 2 clinical trial, titled "NP-G2-044 as Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies," is currently ongoing and approaching completion.

About Novita 
Novita Pharmaceuticals, Inc. ("Novita" or the "Company") is a privately held, clinical-stage biopharmaceutical company focused on developing groundbreaking therapies using its proprietary fascin inhibitor technology to prevent and treat cancer metastasis while simultaneously enhancing anti-cancer immune responses. For more information, visit www.novita-pharm.com/.

Media Contact:
Argot Partners (media)
David Rosen
212.600.1902
[email protected]

Investor Contact: 
Argot Partners (investors)
Noor Pahlavi
212.600.1902
[email protected]

SOURCE Novita Pharmaceuticals, Inc.